5225
IHH Healthcare Berhad
Sector: Healthcare | Market: MAIN
Key Financials
Extracted from official Bursa Malaysia quarterly filings. Latest 4 quarters, side by side.
Q4 FY2025Q3 FY2025Q2 FY2025Q1 FY2025
Income Statement
| Metric | Q4 FY2025 RM '000 | Q3 FY2025 RM '000 | Q2 FY2025 RM '000 | Q1 FY2025 RM '000 |
|---|---|---|---|---|
| Revenue | 25,745 | 6,570 | 6,298 | 6,294 |
| Other operating income | 551 | 109 | 96 | 101 |
| Inventories and consumables | -5,225 | -1,336 | -1,292 | -1,274 |
| Purchased and contracted services | -2,062 | -526 | -522 | -482 |
| Staff costs | -9,921 | -2,468 | -2,451 | -2,515 |
| Depreciation and impairment of property, plant and equipment | -1,406 | -359 | -342 | -347 |
| Depreciation of right-of-use ("ROU") assets | -452 | -117 | -108 | -111 |
| Amortisation of intangible assets | -53 | -12 | -12 | -12 |
| Operating lease expenses | -144 | -34 | -32 | -31 |
| Other operating expenses | -3,153 | -783 | -743 | -746 |
| Finance income | 200 | 33 | 69 | 57 |
| Finance costs | -1,086 | -277 | -257 | -282 |
| Net monetary gain arising from hyperinflationary economy | 402 | 245 | 15 | 103 |
| Share of profits of associates (net of tax) | 29 | 7 | 8 | 6 |
| Share of profits of joint ventures (net of tax) | 3 | 1 | 0 | 1 |
| Profit before tax | 3,428 | 1,053 | 727 | 762 |
| Income tax expense | -821 | -264 | -160 | -137 |
| Profit for the period | - | 789 | 567 | 625 |
| Profit for the year | 2,607 | - | - | - |
| Profit attributable to owners of the Company | - | 616 | 443 | 514 |
| Earnings per share (Basic) (sen) | 0 | - | - | - |
| Profit attributable to non-controlling interests | - | 173 | 124 | 111 |
| Earnings per share (Diluted) (sen) | 0 | - | - | - |
| Earnings per share (Basic) | - | - | 0.005 | - |
| Basic EPS (3rd quarter ended 30 Sep 2025) | - | 0.007 | - | - |
| Basic earnings per share (sen) | - | - | - | 0.006 |
| Basic EPS (Financial period ended 30 Sep 2025) | - | 0.018 | - | - |
| Earnings per share (Diluted) | - | - | 0.005 | - |
| Diluted earnings per share (sen) | - | - | - | 0.006 |
| Diluted EPS (3rd quarter ended 30 Sep 2025) | - | 0.007 | - | - |
| Diluted EPS (Financial period ended 30 Sep 2025) | - | 0.018 | - | - |
Balance Sheet
| Metric | Q4 FY2025 RM '000 | Q3 FY2025 RM '000 | Q2 FY2025 RM '000 | Q1 FY2025 RM '000 |
|---|---|---|---|---|
| Assets | 0 | 0 | 0 | 0 |
| Property, plant and equipment | 17,665 | 17.543 | 16,904 | 16,597 |
| Right-of-use assets | 7,781 | 7.609 | 7,370 | 7,526 |
| Investment properties | 4,521 | 4.682 | 4,743 | 4,779 |
| Goodwill on consolidation | 15,639 | 16.087 | 16,094 | 16,257 |
| Other intangible assets | 3,851 | 3.783 | 3,657 | 3,611 |
| Interests in associates | 167 | 0.159 | 144 | 140 |
| Interests in joint ventures | 15 | 0.018 | 18 | 19 |
| Other financial assets | 692 | 0.687 | 513 | 794 |
| Trade and other receivables | 3,365 | 3.591 | 3,523 | 3,520 |
| Tax recoverables | 191 | 0.118 | 113 | 90 |
| Derivative assets | 15 | 0.01 | 96 | 97 |
| Deferred tax assets | 302 | 0.226 | 356 | 361 |
| Total non-current assets | 50,960 | 51.141 | 50,297 | 50,374 |
| Development properties - medical suites | 80 | 0.08 | 80 | 80 |
| Inventories | 719 | 0.708 | 674 | 701 |
| Cash and cash equivalents | 1,595 | 1.465 | 1,534 | 1,536 |
| Total current assets | 6,657 | 6.659 | 6,533 | 6,818 |
| Total assets | 57,617 | 57.8 | 56,830 | 57,192 |
| Equity | 0 | 0 | 0 | 0 |
| Share capital | 19,894 | 19.894 | 19,894 | 19,774 |
| Other reserves | -405 | 0.233 | 432 | 721 |
| Retained earnings | 10,814 | 10.335 | 10,136 | 9,739 |
| Total equity attributable to owners of the Company | 30,303 | 30.462 | 30,462 | 30,234 |
| Non-controlling interests | 3,798 | 3.758 | 3,786 | 3,737 |
| Total equity | 34,101 | 34.22 | 34,248 | 33,971 |
| Liabilities | 0 | 0 | 0 | 0 |
| Loans and borrowings | 5,598 | 2.785 | 2,510 | 4,079 |
| Lease liabilities | 200 | 0.263 | 256 | 255 |
| Employee benefits | 205 | 0.182 | 161 | 177 |
| Trade and other payables | 4,939 | 5.081 | 4,310 | 4,671 |
| Derivative liabilities | 37 | 0.005 | 2 | 27 |
| Deferred tax liabilities | 1,840 | 1.668 | 1,605 | 1,653 |
| Total non-current liabilities | 12,122 | 14.923 | 14,905 | 13,563 |
| Bank overdrafts | 52 | 0.031 | 46 | 21 |
| Tax payable | 363 | 0.31 | 392 | 455 |
| Total current liabilities | 11,394 | 8.657 | 7,677 | 9,658 |
| Total liabilities | 23,516 | 23.58 | 22,582 | 23,221 |
| Total equity and liabilities | 57,617 | 57.8 | 56,830 | 57,192 |
Cash Flow Statement
| Metric | Q4 FY2025 RM '000 | Q3 FY2025 RM '000 | Q2 FY2025 RM '000 | Q1 FY2025 RM '000 |
|---|---|---|---|---|
| Cash flows from operating activities | 0 | 0 | 0 | 0 |
| Profit before tax | 3,428 | 2,542 | 1,489 | 762 |
| Adjustments for: | 0 | 0 | 0 | 0 |
| Dividend income | -1 | -1 | -1 | - |
| Finance income | -200 | -159 | -126 | -57 |
| Finance costs | 1,086 | 816 | 539 | 282 |
| Depreciation and impairment of property, plant and equipment | 1,406 | 1,048 | 689 | 347 |
| Depreciation of ROU assets | 452 | 336 | 219 | 111 |
| Amortisation of intangible assets | 53 | 36 | 24 | 12 |
| Impairment loss made: Goodwill | 5 | - | - | - |
| Impairment loss made: | - | - | 0 | 0 |
| Impairment loss made: Trade and other receivables | 99 | 78 | - | - |
| - Trade and other receivables | - | - | -312 | -201 |
| Write-off: | - | - | 0 | 0 |
| Write-off: Property, plant and equipment | 2 | 1 | - | - |
| Write-off: Trade and other receivables | 40 | 11 | - | - |
| - Property, plant and equipment | - | - | 1 | 1 |
| Write-off: Inventories | 6 | 4 | - | - |
| Gain on disposal of property, plant and equipment | -2 | - | -3 | -1 |
| - Inventories | - | - | -54 | -48 |
| Loss on disposal of interests in joint ventures | 5 | - | - | - |
| Gain on disposal of asset | 0 | 0 | 0 | 0 |
| Loss/(Gain) on disposal of property, plant and equipment | - | 1 | - | - |
| Change in fair value of investment properties | -89 | 0 | - | 1 |
| Share of profits of associates (net of tax) | -29 | -21 | -14 | -6 |
| Reversal of impairment for investment in an associate | -15 | -11 | - | - |
| Share of profits of joint ventures (net of tax) | -3 | -2 | -1 | -1 |
| Reversal of provision for loan taken by a joint venture | 0 | - | - | - |
| Equity-settled share-based payment | 1 | 1 | 1 | 1 |
| Net monetary gain arising from hyperinflationary economy | -402 | -363 | -118 | -103 |
| Operating profit before changes in working capital | 5,819 | 4,317 | 2,746 | 1,376 |
| Gain on bargain purchase | -23 | - | - | - |
| Changes in working capital: | - | - | 0 | 0 |
| Changes in working capital: Inventories | -135 | -97 | - | - |
| Trade and other payables | - | - | 420 | 27 |
| Changes in working capital: Trade and other receivables | -545 | -501 | - | - |
| Cash generated from operations | 6,233 | 4,922 | 2,800 | 1,154 |
| Tax paid | -659 | -536 | -319 | -58 |
| Changes in working capital: Trade and other payables | 1,094 | 1,203 | - | - |
| Net cash from operating activities | 5,574 | 4,386 | 2,481 | 1,096 |
| Cash flows from investing activities | 0 | 0 | 0 | 0 |
| Interest received | 177 | 130 | 93 | 51 |
| Acquisition of a subsidiary, net of cash and cash equivalents acquired | - | - | 0 | 0 |
| Purchase of other financial assets | -2,480 | -1,647 | -945 | -462 |
| Net placement of fixed deposits with tenor of more than 3 months | - | -46 | -42 | -55 |
| Acquisition of subsidiaries and a business, net of cash and cash equivalents acquired | -293 | - | - | - |
| Acquisition of a subsidiary and business, net of cash and cash equivalents acquired | - | -307 | - | - |
| Purchase of property, plant and equipment | -3,446 | -2,944 | -2,012 | -899 |
| Advance payment for acquisition of a subsidiary | -59 | - | - | - |
| Cost capitalised and purchase of investment properties | -22 | -22 | -20 | -3 |
| Development and purchase of intangible assets | -231 | -131 | -123 | -32 |
| Net withdrawal/(placement) of fixed deposits with tenor of more than 3 months | 56 | - | - | - |
| Proceeds from disposal of other financial assets | 2,537 | 1,809 | 1,281 | 546 |
| Proceeds from disposal of property, plant and equipment | 60 | 13 | 2 | 0 |
| Proceeds from disposal of asset | 0 | 0 | 0 | 0 |
| Proceeds from disposal of interests in joint ventures | 4 | - | - | - |
| Net cash used in investing activities | -3,694 | -3,143 | -1,764 | -854 |
| Cash flows from financing activities | 0 | 0 | 0 | 0 |
| Dividends received from associates and joint ventures | 3 | 2 | 2 | - |
| Finance costs paid | -700 | -467 | -310 | -143 |
| Proceeds from loans and borrowings | 6,664 | 3,814 | 2,683 | 1,622 |
| Repayment of loans and borrowings | -5,670 | -2,666 | -1,747 | -804 |
| Payment of lease liabilities | -434 | -517 | -196 | -122 |
| Dividends paid to non-controlling interests | -185 | -178 | -40 | -38 |
| Proceeds from exercise of share options | 136 | 136 | 136 | 28 |
| Dividends paid to owners of the Company | -927 | -485 | -485 | - |
| Acquisition of non-controlling interests | -687 | -687 | -686 | -692 |
| Proceeds from issue of shares by a subsidiary to non-controlling interests | 15 | 14 | 14 | 15 |
| Net cash used in financing activities | - | -912 | -631 | -134 |
| Net increase/(decrease) in cash and cash equivalents | 205 | 331 | 86 | 108 |
| Effect of exchange rate fluctuations on cash and cash equivalents held | -89 | -324 | -25 | -20 |
| Proceeds from capital injection by non-controlling interests | 0 | 0 | 0 | - |
| Cash and cash equivalents at beginning of the period | - | 1,427 | 1,427 | 1,427 |
| Cash and cash equivalents at end of the period | - | 1,434 | 1,488 | 1,515 |
| Proceeds from settlement of derivatives | 113 | 124 | - | - |
| Net cash (used in)/from financing activities | -1,675 | - | - | - |
| Cash and cash equivalents at beginning of the year | 1,427 | - | - | - |
| Cash and cash equivalents at end of the year | 1,543 | - | - | - |
Investor Solutions
What's slowing down your research?
We're building customized tools for investors. Tell us your biggest challenge and we'll let you know when we solve it.